Vera Therapeutics (NASDAQ:VERA) Price Target Lowered to $96.00 at JPMorgan Chase & Co.

Vera Therapeutics (NASDAQ:VERA) had its target price trimmed by JPMorgan Chase & Co. from $99.00 to $96.00 in a research report released on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities analysts have also issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a report on Friday. Pivotal Research set a $73.00 price objective on Vera Therapeutics in a research report on Friday, December 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a research note on Friday, November 28th. Finally, Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Price Performance

VERA opened at $51.22 on Friday. The firm has a market capitalization of $3.27 billion, a PE ratio of -12.84 and a beta of 1.21. The business’s 50-day moving average is $33.89 and its two-hundred day moving average is $27.30. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter last year, the company posted ($0.85) EPS. Research analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, Director Patrick G. Enright purchased 5,882 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the acquisition, the director owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. The trade was a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in shares of Vera Therapeutics by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after buying an additional 377,783 shares during the last quarter. Deerfield Management Company L.P. raised its position in Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Vera Therapeutics by 6.3% in the third quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after acquiring an additional 189,545 shares during the period. Vestal Point Capital LP boosted its position in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its position in Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after purchasing an additional 550,000 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.